At the news
? BULLISHIMPACT 6/10 8-K filed Nov 9, 2026 at 07:19 ET
Faeth Therapeutics announced positive preliminary Phase 2 topline results for PIKTOR (serabelisib + sapanisertib) plus paclitaxel in advanced endometrial cancer. The trial met its primary endpoint with a 33% confirmed ORR and 7.4-month median PFS in a heavily pretreated population. The company plans to advance to a Phase 3 registrational trial, subject to regulatory alignment.
- Confirmed ORR of 33% (12 of 36 efficacy-evaluable patients) in advanced endometrioid endometrial cancer
- Among PIK3CA-mutation patients, confirmed ORR was 44% (7 of 16)
- Preliminary median PFS of 7.4 months (95% CI 5.3-NR) and 6-month PFS rate of 62%
- Disease control rate (DCR) of 83% (30 of 36)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access